“MERRY JANE” and “HIGH TIME” ARTICLES ON DOYEN ELEMENTS, INC.’S PUEBLO, COLORADO FACILITY

July 21, 2017

Dear Shareholder,

MERRY JANE & HIGH TIMES published articles on Doyen Elements, Inc.’s (f.k.a-AdvantaMeds Solutions) Pepsi factory pending conversion into a massive marijuana grow facility.

Article #1- Merry Jane- Date July 21, 2017- Title- ” Abandoned Colorado Pepsi Plant to Become 100,000 Square Foot Grow House.”

Link: https://merryjane.com/news/colorado-giant-grow-house-abandoned-pepsi-plant

Article #2- High Times-July 21, 2017-Title- “Abandoned Pepsi Factory Turned into Massive Grow Op.”

Link: http://hightimes.com/news/abandoned-pepsi-factory-turned-into-massive-grow-op/

If you have further question regarding both of these publications, contact 757-306-6090 and yes@yesinternational.com.

With Warmest Regards,

/s/

Rich Kaiser
Investor Relations
Doyen Elements
www.doyenelements.com
(Under Investor Relations Contract-YES INTERNATIONAL)
757-306-6090
yes@yesinternational.com

New Corporate website- www.doyenelements.com (Under Construction).

Forward-Looking Statements:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

This Press Release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These “forward-looking statements” that address activities, events or developments that Doyen Elements, Inc. expects, anticipates, or estimates may occur in the future. Generally forward-looking statements by words such as “may,” “will,” “would,” “could,” “continue,” “potential,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions. There are a numerous risks and uncertainties, both known and unknown, that could cause actual results to differ materially from the results implied by the forward-looking statements, which may include but are not limited to, business risks, general industry conditions and competition, general economic factors, governmental actions, legislative conditions, the impact of cannabis industry regulation, legislation in the United States and internationally and technological advances. Doyen Elements undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise

“BUSINESS INSIDER” ARTICLE-DOYEN ELEMENTS, INC. (f.k.a-AdvantaMed)

“BUSINESS INSIDER” ARTICLEJuly 18, 2017

Dear Shareholder,

The following link provides a “BUSINESS INSIDER” article on Doyen Elements, Inc. (f.k.a-AdvantaMeds Solutions) entitled An abandoned Pepsi factory is being turned into a massive marijuana grow.”

Article- BUSINESS INSIDER- Date: July 18, 2017- Title: “An abandoned Pepsi factory is being turned into a massive marijuana grow

http://www.businessinsider.com/abandoned-pepsi-factory-turned-marijuana-farm-2017-7/#for-many-years-the-104000-square-foot-plant-at-1900-south-freeway-was-used-for-bottling-pepsi-products-but-the-soda-company-like-the-steel-industry-left-pueblo-county-1

If you have further question regarding this publication, contact 757-306-6090 and yes@yesinternational.com.

With Warmest Regards,

/s/

Rich Kaiser
Investor Relations
Doyen Elements
www.doyenelements.com
(Under Investor Relations Contract-YES INTERNATIONAL)
757-306-6090
yes@yesinternational.com

New Corporate website- www.doyenelements.com (Under Construction).

Forward-Looking Statements:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

This Press Release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These “forward-looking statements” that address activities, events or developments that Doyen Elements, Inc. expects, anticipates, or estimates may occur in the future. Generally forward-looking statements by words such as “may,” “will,” “would,” “could,” “continue,” “potential,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions. There are a numerous risks and uncertainties, both known and unknown, that could cause actual results to differ materially from the results implied by the forward-looking statements, which may include but are not limited to, business risks, general industry conditions and competition, general economic factors, governmental actions, legislative conditions, the impact of cannabis industry regulation, legislation in the United States and internationally and technological advances. Doyen Elements undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Bravo Multinational Incorporated (BRVO) Files its March 31, 2017, Quarterly Report, Preferred ‘A’ Shares Cancelled

Toronto, Canada- July 11, 2017- Bravo Multinational Incorporated (OTCPINK: BRVO) filed its first quarter ending, March 31, 2017, FORM 10-Q with the US SEC.  Subsequently, the Company’s filing status is now revised to “Current Reporting.”

Currently, Bravo’s accountants are proceeding with the preparation of the 2nd quarterly FORM 10-Q filing, expected to be submitted before the due date of August 14, 2017.

On June 18, 2017, 100% of the Preferred ‘A’ shareholders agreed to have ALL of their Preferred ‘A’ shares (issued and outstanding) returned to Bravo treasury for cancellation; no monetary value was recognized for these share returns.  The result of this action returns 100% voting control of the Company to the shareholders of outstanding common stock.

On May 30, 2017, the Company advanced 100 additional slot and video poker gaming machines as part of the bulk purchase agreement signed on May 4, 2016.  All gaming machines once retailed are to be operated and managed under a long-term (the year 2033) countrywide national license. Delivery was advanced to fill additional orders for retail sales and reports on these new “Closed Sales” in upcoming US SEC filings.

The Company is progressing well with its review of the business opportunity reported in its June 26, 2017, press release.  The “Letter of Intent” stipulates the potential purchase of plenty of gaming machines available for immediate revenue producing placement.  Management will release a news update upon completing a definitive contract agreement on the pending gaming machine purchase.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTC: BRVO) is a diversified company with its main focus being on the growth of its casino gaming equipment holdings. Current BRVO gaming equipment assets are located in Central and South America. Bravo also holds patented mining claims in the gold and silver district on War Eagle Mountain, USA. Bravo’s current and future growth strategy, driven by partnerships, new acquisitions, and ventures should result in financially viable and profitable long- term operations throughout the Americas.

For further information contact Bravo Multinational Incorporated, www.bravomultinational.com, info@bravomultinational.com and (716) 803-0621

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by other factors. Such factors, including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Bravo Multinational Incorporated’s (BRVO) FORM 10-K Reports $741,945 Revenue, Advances Gaming Machine Orders, and Sign “Letter of Intent”

Toronto, Canada, -June 26, 2017- Bravo Multinational Incorporated (OTCPINK.BRVO) on June 23, 2017, announces filing its US SEC FORM 10-K for the year-end December 31, 2016.

For the year-ending December 31, 2016, the Corporation reported audited revenue of $741,845 from the sale of casino gaming equipment.

The Corporation’s new PCAOB auditor completed the audited financial statements for the periods ending December 31, 2015, and 2016.

The recent auditor changes were related directly to the inability of the former auditors and accountants to provide BRVO with fully audit services as required by a PCAOB auditing firm under US SEC reporting rules.  Therefore, BRVO had no choice but to contract a new accounting firm and a PCAOB Auditor. That move required a full two-year audit.

Management now moves forward with getting its FORM 10-Q filed for the period ending March 31, 2017.  With the immediate objective to file this report becoming full reporting and update to a “Current” status on OTCMARKETS.COM again, this remains a fiduciary priority, and BRVO apologizes for these reporting delays.

With marketing increases, BRVO’s sales continue to advance, whereas, on March 29, 2017, BRVO advanced 100 additional slot and video poker gaming machines as part of the casino gaming equipment “Purchase Agreement” signed on May 4, 2016.  Delivery advanced to fill immediate retail sales orders with all new ‘closed sales’ reported in the upcoming US SEC FORM 10-Q filings.  All retailed gaming machines will continue to operate and managed under a long-term (the year 2033) country-wide national license.

Management’s focused growth in the casino gaming sector enabled the signing of a

‘Letter of Intent’ (LOI) on May 30, 2017.  The proposed LOI structures a large acquisition of casino gaming equipment currently available for immediate placement into licensed operations. Management believes that based on historical equipment revenue statistics, that upon equipment placement, BRVO should greatly benefit from an immediate positive cash flow. These pending assets would remain in BRVO.

Upon preparation and full approval, BRVO’s management intends on closing the transaction in July 2017.

Bravo’s CEO, Paul Parliament, stated, “BRVO’s executives remain confident and optimistic that all recent actions are solid long-term technical moves which should lead to solid, steady future results.” He further states, “recent recapitalization actions provides quantifiable share price valuation, providing BRVO shareholders a more accurate market view on our business activities.”

Company performances facilitated through the growth of retail operations, the staged acquisitions of casino equipment operations, and the potential expansion of several additional multifaceted business acquisition opportunities (currently under review) became available as a direct result of recent operational changes and recapitalization.  Bravo anticipates several new business ventures to be in place throughout 2017 and beyond.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with its main focus on the development and expansion of the Casino Gaming Equipment holdings and Gaming related business activities throughout Central and South America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

 

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

 

DOYEN ELEMENTS: MEDICAL CANNABIS HOLDING COMPANY UNDER CONTRACT TO ACQUIRE 16 COMPANIES IN COLORADO

Advantameds Solutions USA Fund 1, Inc. changes its name to Doyen Elements better reflecting its focus as a Full-Service Real Estate Investor and Cannabis Consultancy Firm through the Acquisition of 16 Cannabis Portfolio Companies 

CHICAGO, IL-June 14, 2017-  Doyen Elements, previously Advantameds Solutions USA Fund 1, Inc., announced today that it is under contract to acquire 16 ancillary cannabis (non-plant touching) operating entities. Doyen Elements has emerged as a full-service consultancy company for the Cannabis industry, further establishing itself as an industry changing investment vehicle.  Doyen Elements provides canna-businesses with real estate investments, full-service management, financial, operational, technology and automation services.  The management team of the 16 portfolio companies that will comprise Doyen Elements brings expertise, including vertical market solutions, cultivation facilities, and other support businesses.

The company has created a total business ecosystem for the Cannabis industry by establishing the 5 Pillars that make up Doyen Elements and the services offered:

  • Real Estate Services – Doyen continues to acquire real estate entities and develop assets. These assets will be utilized by license holders that are legal in their respective space and to easily scale cultivation efforts for those legally selling cannabis. Doyen Elements is expecting to have 1 million square feet in their portfolio by 2021. Additionally, the company provides a means for wholesale distribution by accelerating and increasing the growth and yield of product for distribution.
  • Consulting and Management Services – With over 9 years of full-scale operational experience in the cannabis industry, Doyen Elements offers industry-leading consulting and management services. Expertise ranges from immediate start-up business activation and licensing, growth structure, tenant improvements, general management, security, transportation, compliance and legal services. Doyen Elements not only provides a detailed roadmap for existing companies seeking to address these issues but have teams in place that can roll up their sleeves to provide Clients with tactical action-oriented assistance in any start-up.
  • Research and Development – When the acquisitions are complete, Doyen’s exclusive patent licensing agreement for the use of the Transdermal Patch will provide national distribution opportunities to the cannabis industry. The company intends to use of this to benefit Doyen business partners, who will leverage this patent when seeking to provide a solution for those suffering from ailments or chronic illnesses that may benefit from the use of transdermal patches.
  • Industrial Equipment – Utilizing the chain of successful stores known as Hydroponics Depot, Doyen intends to sell hydroponic equipment, nutrients, additives etc. required to operate clean, high-quality cultivation facilities.
  • Working Capital and Green Construction Operations – Doyen Elements will utilize its construction expertise and provide LEED Certifiable solutions in the building of cultivation facilities and retail structures. Syntheto Foam System, which has proven to be mold and pest resistant and will more than double the R-Factor of the entire structure.   The Company will also provide its clients with innovative green construction solutions that not only help decrease operational costs but will also provide maximum growing and cultivation ease.

“We are delighted to announce the formation of Doyen Elements,” says Chief Operating Officer Cindy Boerum.  “Doyen will bring stature and speed to the entire burgeoning cannabis ecosystem. By creating a consultancy that provides category-defining business acumen and direct access to an experienced management team with hands-on operational experience, the Company will provide nascent and middle market cannabis ventures with the cross-functional know-how needed to quickly accelerate their canna-businesses. “

The addition of the vertices will not only allow the company to offer the best in class services to ‘Canna-businesses,’ but offer investors a vehicle to invest in the top management teams within the growing Cannabis space, and provide a diverse portfolio of industry-leading Cannabis support businesses for investors through full-service management, financial, operational, and execution services.

For additional information about Doyen Elements, Inc. direct investment offering, contact Rich Kaiser, Investor Relations YES INTERNATIONAL 757-306-6090 yes@yesinternational.com

Forward-Looking Statements:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

This Press Release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.  These “forward-looking statements” that address activities, events or developments that Doyen Elements, Inc. expects, anticipates, or estimates may occur in the future.  Generally forward-looking statements by words such as “may,” “will,” “would,” “could,” “continue,” “potential,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend” and other similar expressions. There are a numerous risks and uncertainties, both known and unknown, that could cause actual results to differ materially from the results implied by the forward-looking statements, which may include but are not limited to, business risks, general industry conditions and competition, general economic factors, governmental actions, legislative conditions, the impact of cannabis industry regulation, legislation in the United States and internationally and technological advances.  Doyen Elements undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

NORTHSTAR ELECTRONICS, INC.’S  (NEIK) CEO DR. WILSON RUSSELL PARTICIPATED IN THE 2017 CANSEC GLOBAL DEFENSE AND SECURITY TRADE SHOW

Virginia Beach, VA- June 13, 2017-  Northstar Electronic, Inc’s (OTCQB:NEIK) CEO, Dr. Wilson Russell, recently participated in the 2017 CANSEC Global Defense and Security trade show in Ottawa, Canada.

Throughout the show, the international aerospace company whose subsidiary has been dealing with Northstar’s subsidiary, Northstar Sealand Enterprises Ltd (NSEL), had a strong presence.

NSEL’s objective is to acquire the exclusive worldwide rights to an enhanced version of a single engine Turbo-Prop industrial airplane from the subsidiary of the international aerospace company.

Dr. Russell had meetings with senior people from the international aerospace company including the Vice President of Sales, the Vice President of Marketing, the Manager of Industrial Cooperation, and the Head of Military Aircraft in Canada along with other responsibilities in North America.

Primarily, meetings were focused on the actions remaining to move forward to an agreement with the international aerospace company’s subsidiary.

Dr. Russell states, “the meetings went well, and based on the information gathered from these meetings and correspondence with the subsidiary, it appears that they could be ready in the next few weeks to move forward to the next steps required to closing a formal agreement.”

The international company has strong and compelling reasons to see their subsidiary and NSEL sign an agreement.  Doing so could improve the international company’s chances at winning certain multi-billion dollar aviation contracts in North America.

For further information about this news release contact,  Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com.

About Northstar Electronics, Inc.

Northstar Electronics, Inc. (OTCQB.NEIK) established in the late 1990’s carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its sonar-based system to commercial customers. Since the termination of the above contracts, Northstar has been seeking other strategic relationships,www.northstarelectronics.com.

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

Predictive Technology Group, Inc.’s (PRED) Development Partner Presents Compelling Genetic Data – World Congress on Endometriosis

Further Progress Toward Development of ARTGuide® Test

Salt Lake City, UT — (May 31, 2017) –Predictive Technology Group, Inc.’s (OTC PINK: PRED) partner Juneau Biosciences, LLC presented four research studies at the 13th World Congress on Endometriosis in Vancouver, Canada. These presentations documented recent progress in developing a non-invasive test for endometriosis.

The presentations Included:

  • VARIATION IN INNATE PAIN SENSITIVITY MAY PLAY AN IMPORTANT ROLE IN ENDOMETRIOSIS
  • PROGRESS TOWARD DEVELOPMENT OF A NON-INVASIVE PREDICTOR FOR ENDOMETRIOSIS 
  • CCDC168 AND MUC12 GENES SHOW RECESSIVE EFFECTS IN WOMEN WITH ENDOMETRIOSIS
  • ENDOMETRIOSIS GWAS REPLICATE ASSOCIATION NEAR THE KINASE INSERT DOMAIN RECEPTOR GENE (KDR)

In 2016, Predictive Therapeutics signed a license agreement with Juneau Biosciences, LLC for the commercialization of assays and related services for the prediction of endometriosis, and other health concerns, in the infertility market. This license extended the close relationship between the two companies.

Given these developments, Predictive Therapeutics and Juneau Biosciences are now poised to launch their novel ARTGuide® test for women experiencing infertility Commercial launch in the United States is now expected during H2 2017.

Bradley Robinson, PRED CEO states: “We look forward to the commercialization of the scientific developments that were presented at the World Congress on Endometriosis in Vancouver, Canada.  The incorporation of these advancements into the ARTGuide® test has the potential to assist fertility specialists in designing the optimal course of care for couples struggling with fertility while transforming the global fertility market.  ARTGuide® will provide “must-have” information for affected couples and their physicians.”

The ARTGuide® test is expected to change the way that advanced reproductive technologies (“ART”) such as In Vitro Fertilization (“IVF”) are used to help couples struggling to have a baby.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States.  Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis.  Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life.  Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women with endometriosis suffer for over a decade before receiving treatment.  Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women’s health care. Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions.
Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women.

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. ( PRED ), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL at 757-306-6090,yes@yesinternational.com,www.predictivetechnologygroup.com,www.predrx.com, www.predbiotech.com, and www.yesinternational.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Weyland Tech’s (WEYL) Partner MOCAAPP Announces Application Sales in the Philippines and Start of Vietnam Marketing

Hong Kong- April 27, 2017- Weyland Tech Inc. (OTCQB: WEYL) (“Weyland” or the “Company”), a provider of mobile business applications, announces initial subscriptions and revenues from its South East Asian partner, MOCAAPP. Marketing and development of additional applications – powered by CreateApp – continues in the Philippines through the Company’s white label channel partner.

According to the Department of Trade and Industry, the Philippines is home to nearly 90,000 Small and Medium businesses (“SMB’s”) and ~900,000 MSMBs (Micro-Small-Medium-sized-Business) overall. Weyland believes that a substantial number of these businesses will ultimately choose to expand their reach through mobile commerce (m-commerce), which has been the case in the US, Europe, and North Asia.

Leong Yew Poh, Chairman of Weyland’s channel partner – MOCAAPP said, “We are pleased with the ease of use and flexibility of the CreateApp platform and are encouraged by the initial marketing efforts in our partnership with Weyland announced in October of last year.

Concurrently, MOCAAPP indicated initial marketing and trade show efforts have begun in Vietnam.

Weyland believes the expansion of m-commerce in South East Asia is in the early stages and is working with their channel partners to become the mobile on-ramp for e-commerce in the region.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.cominfo@weyland-tech.com, and http://www.weyland-tech.com/.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements.” The statements regarding the continued growth of the mobile app segment and the ability of the Company to continue its expansion into that segment and the ability of the Company to attract customers and partners and generate revenues. Often these forward-looking statements are identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). Expressly, all forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Development of ARTGuide® Test Will Rapidly Accelerate Short-Term Company Growth

Salt Lake City, UT — (January 18, 2017) – Predictive Therapeutics, LLC, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, was formally notified by its research and development partner, Juneau Biosciences, LLC that a key product development milestone has been reached — the sensitivity and specificity of the ARTGuide® predictive test has passed a critical clinical threshold.  Details of this achievement will remain confidential until a scheduled scientific presentation at the upcoming World Congress of Endometriosis to be held in Vancouver, Canada in May 2017.  Predictive Therapeutics will continue to provide development and financial support to Juneau to allow final validation of these “Laboratory Developed Tests” (LDTs) under “Clinical Laboratory Improvement Amendments” (CLIA) guidelines

In 2016, Predictive Therapeutics signed a license agreement with Juneau Biosciences, LLC for the commercialization of assays and related services for the prediction of Endometriosis, and other health concerns, in the infertility market. This license extends the close relationship between the two companies.

Given these developments, Predictive Therapeutics and Juneau are now poised to launch their novel test for women experiencing infertility, called ARTGuide®. The ARTGuide® Test is expected to change the way that Advanced Reproductive Technologies (ART) such as In Vitro Fertilization (IVF) is used to help couples struggling to have a baby.  The commercial launch of the ARTGuide® infertility test in the United States is now expected during Q3 2017.

Bradley Robinson, PRED CEO states, “I am quite certain that the ARTGuide® Test has the potential to increase the likelihood that couples struggling with infertility will be more successful at becoming pregnant, which could dramatically transform this lucrative infertility market.  The ARTGuide® Test will provide ‘must-have’ information for affected couples and their physicians.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States.  Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis.  Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life.  Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women with endometriosis suffer for over a decade before receiving treatment.  Treatment may involve hormonal suppression or the targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women’s health care. 
 Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions. 

Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women. 

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. ( PRED ), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about the release contact, Mr. Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

 

Northstar Electronics Recap of Main Events of 2016

Virginia Beach, VA, Jan. 10, 2017 (GLOBE NEWSWIRE) — Northstar Electronics, Inc.(NEIK:OTCQB), the “Company”,  provides a Recap of the main events of 2016.

To summarize, the Company’s primary objectives for 2016 were two fold. One was to improve the Company’s standing as a publicly traded platform. The second was to make significant progress for the Company’s subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), to secure the exclusive worldwide ownership rights to the enhanced version of a single engine Turbo-Prop industrial airplane owned by the subsidiary of a major international aerospace company. NSEL intends to manufacture, market and sell the airplane and also carry out Maintenance, Repair and Overhaul (MRO) services.

During the year, the Company achieved its goals of becoming current with its SEC filings and returning to the OTCQB trading platform, actions fundamental to the Company’s future success.

With respect to the acquisition of the rights to the airplane, significant progress was made on key matters. Agreement with the aerospace company subsidiary was reached during the year on the main technical issues. As well, strong progress was made on project scheduling and cost estimates.

At year’s end, NSEL and the aerospace company subsidiary signed a milestone Memorandum of Understanding (MOU). The MOU outlines the key actions and goals to be reached in order for both parties to implement their business plans going forward. The signing of this MOU is a major step which ultimately should lead to NSEL reaching its manufacturing and marketing objectives within a reasonable time frame.

GOALS FOR 2017

The Company’s goals for NSEL in 2017 are to finalize the acquisition of the exclusive worldwide rights to the Turbo Prop industrial airplane and initiate the transfer of the Type Certificate to NSEL, to initiate the establishment of first order technical support, to put in place a Supply Chain Management system, to initiate the marketing campaign and to secure the first sales orders for the airplane.

We will be approaching institutional investors and venture capital companies for the funding needed to grow the company. As well, we will explore funding opportunities through certain government support programs.

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com